Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19824269 | 0.83 | GRIA1 (0.56) | GRIA1ALDH1A1TSHREPHX2L3MBTL1 | |
| SCHEMBL19824303 | 0.82 | ALDH1A1 (0.42) | GRIA1ALDH1A1TSHRPKM | |
| SCHEMBL5907932 | 0.77 | ALDH1A1 (0.38) | GRIA1ALDH1A1TSHREPHX2L3MBTL1 | |
| SCHEMBL968309 | 0.75 | CA1 (0.45) | ALDH1A1TSHREPHX2 | |
| SCHEMBL16448768 | 0.75 | ALDH1A1 (0.38) | GRIA1ALDH1A1TSHREPHX2L3MBTL1 | |
| SCHEMBL12783284 | 0.75 | ALDH1A1 (0.37) | GRIA1ALDH1A1TSHREPHX2L3MBTL1 | |
| SCHEMBL19824268 | 0.74 | GRIA1 (0.46) | GRIA1ALDH1A1 | |
| SCHEMBL27182790 | 0.73 | ALDH1A1 (0.40) | GRIA1ALDH1A1TSHREPHX2L3MBTL1 | |
| SCHEMBL16448770 | 0.71 | EPHX1 (0.47) | ALDH1A1TSHREPHX2L3MBTL1 | |
| SCHEMBL22893223 | 0.69 | EPHX2 (0.36) | ALDH1A1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220088163-A1 | HYBRID IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088163-A1 | HYBRID IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY | RNASE1, DNASE1L3, IPO9 | GRIA1 2541/4885ALDH1A1 4210/4885TSHR 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.